Form PTO-1449 U.S DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (Rev. 2-32)

ATTY DOCKET NO. 7203.01 SERIAL NO. 09/689,621

INFORMATION DISCLOSURE STATEMENT BY APPLICANT everal sheets if necessary)

**APPLICANT** Kent R. Van Kampen et al.

FILING DATE

**GROUP ART UNIT** 1651

October 13, 2000

**U.S. PATENT DOCUMENTS** 

A IRAULA		υ,	J.S. PATENT DOCUMENTS			
Examiner Initial	Document Number	Date	Inventor Name	Class	Sub- class	Fili <b>ng</b> Date (if ap <b>uro</b> priate)
U	4,479,935	10-30-84	Metianu et al.			SE
1	4,746,511	5-24-88	Kobatake et al.			CEN TO
	4,873,090	10-10-89	Clancy			EA T
	6,019,985	2-1-00	Brown et al.			20   16
1	6,221,847 B1	4-24-01	Barefoot et al.			90 91
W	08/912,026		Oral Administration of Bacteria at a Concentration Which Produces Cell – Mediated Immunity and Weight Gain in Certain Animals			2001 1600/2900
				1		

## **FOREIGN PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Country	Class	Sub- class	Translation
				-		No
		,				No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		OTTER DOGGINERT O (Morading Flattion, Files, Date), Formion Pages, Etc.)
Examiner Initial/		Document Description
W	1	ADLAM C. AND M.T. SCOTT, Lympho-reticular stimulatory properties of corynebacterium parvum and related bacteria, J. Med. Microbiol., 6(3):261-74 (1973)
	L	BECKER A. ET AL., Propionibacterium acnes immunotherapy in chronic recurrent canine pyoderma, J. Vet. Intern. Med., 3(1):26-30 (1989)
	4	BELLANTI J. AND J. CLOT, Advances in Ribosomal Immunotherapy, Drugs Supplement, Adis International, 51:Supp 1, 1-49 (1997)
	9	CHRISTIE, G.H. AND R. BOMFORD, Mechanisms of macrophage activation by Corynebacterium parvum, Cell. Immuno., 17: 141-49 (1975)
	5	COX WI, Examining the immunologic and hematopoietic properties of an immunostimulant, Veterinary Medicine, pg. 424-428 (1988)
	le	EVANS, D.R. ET AL., Inactivated Propionibacterium acnes (ImmunoRegulin) as adjunct to conventional therapy in the treatment of equine respiratory diseases, Equine Practice, 10 (6):17-21 (1988)
	7	FLAMINO MJ ET AL., Immunologic function in horses after non-specific immunostimulation administration, Vet. Immonl. Immunopathol., 63(4):303-15 (1998)
17	8	FUJIWARA H. ET AL., Preventative effect of Propionibacterium acnes on metastasis in mice rendered tolerant to tumorassociated transplantation antigens, Gann., 71(5):692-8 (1980)
	9	HALL H. ET AL., Induced regression of bovine papillomas by intralesional immunotherapy, Ther. Immunol., 1(6):319 (1994)

EX	ΛĿ	4II		0
	Μħ	/111	ИC	м

ANKGORD

DATE CONSIDERED 3-12-7

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant,

CD 2 / 2001 A

716

Sheet 2 of 2

Form PTO-1443 (1. S DEPARTMENT OF COMMERCE (Rev. 2-32)

ATTY DOCKET NO. 7203.01 SERIAL NO. 09/689,621

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use several sheets if necessary)

APPLICANT Kent R. Van Kampen et. al

FILING DATE

October 13, 2000

GROUP ART UNIT

1651

TUNIT E P

**U.S. PATENT DOCUMENTS** 

		<u> </u>	7. I ATENT BOOMENTO			
Examiner Initial	Document Number	Date	Inventor Name	Class	Sub- class	Filing ate (if appropriate)
						8

**FOREIGN PATENT DOCUMENTS** 

Examiner Initial	Document Number	Date	Country	Class	Sub- class	Translation
						No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner Initial	Document Description
The	HOLLINGSHEAD AC AND STEWART TH, Specific and nonspecific immunotherapy as an adjunct to curative surgery for cancer of the lung, Yale J. Biol. Med., 54(5):367-79 (1981)
V 7   2	HOWARD, J.G. ET Al., Biological Effects of Corynebacterium parvum, Cell. Immuno. 7, 290-301 (1973)
3	JACKSON RA ET AL., Role of pulmonary macrophages in resistance to experimental metastasis, J. Leukoc. Biol., 40(5):575-87 (1986)
4	LYNCH NR AND SALOMON JC, Tumor growth inhibition and potentiation of immunotherapy by indomethacin in mice, J. Natl. Cancer Inst., 62(1):117-21 (1979)
5	MASUHARA M. J., Expression of hepatocyte growth factor and transforming growth factor beta 1 mRNA in P. acnes and lipopolysaccharide-treated rats, J. Gastroenterol., 30(1):48-54 (1995)
ŧ	MEGID J AND KANENO R, Natural killer activity in mice infected with rabies virus and submitted to P. acnes (Propionibacterium acnes) as immunomodulator, Comp. Immunol. Microbiol. Infect. Dis., 23(2):91-7 (2000)
+	MEGID J ET AL., Effect of bacillus of Calmette-Guerin, avridine and Propionibacterium acnes as immunomodulators on rabies in mice, Rev Inst. Med. Trop. Sao Paulo, 41(2):107-14 (1999)
3	MEGID J ET AL., Effect of the bacillus of Calmette-Guerin, Propionibacter acnes and avridine as immunomodulators in antirables vaccination of mice using the Fuenzalida-Palacios mouse brain vaccine, Vaccine, 17(19):2446-52 (1999)
9	MURANO EA, ET AL., Role of Respiratory-burst products from polymorphonuclear leukocytes in the antitumor activity of Propionibacterium acnes vaccine, Cancer Immunol. Immunother., 29(1):7-16 (1989)
l3	NEIFELD JP ET AL., Adjuvant corynebacterium parvum immunotherapy for squamous cell epitheliomas of the oral cavity, pharynx, and larynx, J. Surg. Oncol., 28(2):137-45 (1985)
11	ROSZKOWSKI W ET AL., Effect of three strains of propionibacteria (P. granulosum, P. avidum, P. acnes) and cell-wall preparations on lymphocytes and macrophages, Zentralbl. Bakterio. A., 246(3):393-404 (1980)
112	VAN KAMPEN KR, Immunotherapy and Cytokines, Seminars in Vet. Med. and Surgery (small animal), 12(3):186-92 (1997)
13	WU Y ET AL., Increased endogenous N-nitrosamine and nitrate formation by induction of nitric oxide synthase in rats with acute hepatic injury caused by Propionibacterium acnes and lipopolysaccharide administration, Carcinogenesis, 14(1):7-10 ZGORNIAK-NOWOSIELSKA I. ET AL., Protection of mice against vaccinia and herpes simplex virus infection by
(i	Propionibacterium acnes, Arch. Immunol. Ther. Exp. (Warsz), 37(3-4):431-2 (1989)

EXAMINER	/	DATE CONSIDERED
	CANGEORS	3-12-2

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Rev 9/18/01